It is the cache of ${baseHref}. It is a snapshot of the page. The current page could have changed in the meantime.
Tip: To quickly find your search term on this page, press Ctrl+F or ⌘-F (Mac) and use the find bar.

Safety and tolerability of tafluprost in treatment of elevated intraoc
skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

14789

Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension



Review

(5818) Total Article Views


Authors: Dorota Pozarowska

Published Date October 2010 Volume 2010:4 Pages 1229 - 1236
DOI: http://dx.doi.org/10.2147/OPTH.S6369

Dorota Pozarowska
Department of Ophthalmology, Medical University, Lublin, Poland

Abstract: Glaucoma is one of the most common neuropathies of the optic nerve. An elevated intraocular pressure (IOP) is a well documented risk factor for the development and progression of this disease. Until now, IOP reduction is the only well documented successful method of glaucoma treatment. Among the many hypotensive drugs, prostaglandin analogs are proved to be the most potent antiglaucoma agents, with very few systemic side effects. A new prostanoid FP receptor analog, tafluprost, has been introduced into the medical treatment of glaucoma and ocular hypertension. Many studies have shown that it is an efficient IOP-lowering drug, and that it is safe and well tolerated. A preservative-free tafluprost formulation is as potent as a preserved one, but it has fewer and milder toxic effects on the eye.

Keywords: tafluprost, prostaglandins, pharmacokinetics, safety, toxic effects, preservatives


Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter


Readers of this article also read: